Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

PREDICTFTD Accelerating the Validation of Predictive Liquid Biomarkers for Frontotemporal Dementia Diagnosis and Subclassification

Coordinator
Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
Runs
1 December 2024 to 31 May 2029
Status
Running
EU funding
€8.0m
Total cost
—
Partners
15 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101156175

What the project is doing

In the project's own words, from its summary on CORDIS.

Frontotemporal dementia (FTD) has a debilitating effect on patients and their caregivers and leads to substantial economic costs. 15-30% of patients have familial FTD caused by known pathogenetic mutations. For the other 70-85% of patients, termed sporadic FTD, diagnosis is slow (~3.6 years) with frequent misdiagnosis due to clinical, genetic and molecular heterogeneity. Thus, there is great need for biomarkers for early diagnosis of sporadic FTD and its pathological subtypes.

In PREDICTFTD, we will validate a set of biomarkers and create a diagnostic tool for early diagnosis of familial and sporadic FTD, which will facilitate tailored support and symptomatic treatments and care. We will apply several new approaches to achieve this: 1) we combine 11 geographically diverse cohorts of sporadic and familial FTD with retrospective and prospective longitudinal liquid biopsy samples and extensive clinical and behavioural data; 2) we are the first to use multimodal clinical and liquid biomarker data to train an AI-algorithm as a diagnostic tool for quick and early clinical FTD diagnosis; and 3) we implement a novel robust two-stage strategy for biomarker and AI algorithm validation, where phase I validates biomarkers and algorithms on a cohort of genetic and autopsied cases and phase II assesses biomarker value for diagnosis of sporadic FTD and at-risk pre-symptomatic mutation carriers.

We will apply this two-stage validation strategy to address three critical clinical challenges: i) To distinguish sporadic FTD from (non-) neurodegenerative disorders that show significant clinical/symptomatic overlap, ii) To robustly detect FTD pathological subtypes in sporadic FTD and iii) pre-symptomatic identification of FTD onset. Thus, PREDICTFTD will transform FTD diagnosis, offering potential for early disease confirmation, guiding treatment decisions, facilitating patient recruitment for clinical trials, guidance of patients and caregivers, and enabling preventive measures.

Who is involved

OrganisationCityCountryRole
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsCoordinator
Csem Centre Suisse D'electronique Et De Microtechnique SA - Recherche Et DeveloppementNeuchatelSwitzerlandAssociatedpartner
Deutsches Zentrum Fur Neurodegenerative Erkrankungen eVBonnGermanyParticipant
Martin-Luther-Universitat Halle-WittenbergHalleGermanyParticipant
Acondicionamiento Tarrasense AssociacionTerrassaSpainParticipant
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Ita-Suomen YliopistoKuopioFinlandParticipant
Fondazione EbrisSalernoItalyParticipant
Universita Degli Studi Di BresciaBresciaItalyParticipant
Universita Degli Studi Di VeronaVeronaItalyParticipant
Uab TeraglobusVilniusLithuaniaParticipant
Alzheimer EuropeSenningerbergLuxembourgParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
The Office of Health EconomicsLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI